Similar articles

• Exaggerated benefits of rosuvastatin compared with other statins.

  Qizilbash N. Qizilbash N. Pharmacoepidemiol Drug Saf. 2009 May;18(5):425-6. doi: 10.1002/pds.1728. Pharmacoepidemiol Drug Saf. 2009. PMID: 19382149 No abstract available.
• [New statin introduction. With more power against hypercholesterolemia].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2002 Dec 12;144(50):64. MMW Fortschr Med. 2002. PMID: 14610873 German. No abstract available.
• HDL cholesterol and residual risk of first cardiovascular events.

  Saely CH, Vonbank A, Drexel H. Saely CH, et al. Lancet. 2010 Nov 20;376(9754):1738; author reply 1738-9. doi: 10.1016/S0140-6736(10)62131-9. Lancet. 2010. PMID: 21093648 No abstract available.
• [C-reactive protein and coronary heart disease: quo vadis?].

  März W, Grammer TB. März W, et al. MMW Fortschr Med. 2009 Oct;151 Suppl 3:127-32. MMW Fortschr Med. 2009. PMID: 20623940 Review. German. No abstract available.
• [JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor].

  Olsson AG. Olsson AG. Lakartidningen. 2009 May 20-Jun 2;106(21-22):1471-5. Lakartidningen. 2009. PMID: 19579435 Review. Swedish. No abstract available.